Sinwisuth Sutheechai, Khanittha Lailakdamrong, P. Sudchada
{"title":"Performance of contrast-associated acute kidney injury predictive risk models in Thai cardiac angiography or angioplasty patients","authors":"Sinwisuth Sutheechai, Khanittha Lailakdamrong, P. Sudchada","doi":"10.29090/psa.2022.05.22.175","DOIUrl":null,"url":null,"abstract":"Several risk prediction models of Contrast-associated acute kidney injury (CA-AKI) in patients undergoing cardiac angiography or angioplasty are available. However, the lack of extensive external validations limits generalizability and clinical acceptance. This study conducted the external validation of three CA-AKI predictive risk models (Chen’s, Inohara’s, and Tziakas’ risk models) and determined the incidence of CA-AKI in Thai patients undergoing cardiac angiography or angioplasty. A total of 647 medical records of patients who underwent elective cardiac angiography (n=446) and angioplasty (n=201) were reviewed. Fifty-five percent were male, mean age 62.6±10.2 years, and mean estimated glomerular filtration rate (eGFR) 69.93±24.30 ml/min/1.73 m2). Incidents of CA-AKI, defined as an absolute increase of serum creatinine of at least 0.3 mg/dL within 48 hours or a relative increase of at least 50% within seven days after the procedure, were collected. The results showed that 78 patients (12.1%) had developed CA-AKI. Chen’s, Inohara’s, and Tziakas’ predictive risk models exhibited low discriminative ability with c-statistic of 0.571, 0.551, and 0.530, respectively. Due to low discriminative capability, these risk models may have low sensitivity to predict CA-AKI in Thai patients undergoing elective cardiac angiography or angioplasty.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Sciences Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29090/psa.2022.05.22.175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Several risk prediction models of Contrast-associated acute kidney injury (CA-AKI) in patients undergoing cardiac angiography or angioplasty are available. However, the lack of extensive external validations limits generalizability and clinical acceptance. This study conducted the external validation of three CA-AKI predictive risk models (Chen’s, Inohara’s, and Tziakas’ risk models) and determined the incidence of CA-AKI in Thai patients undergoing cardiac angiography or angioplasty. A total of 647 medical records of patients who underwent elective cardiac angiography (n=446) and angioplasty (n=201) were reviewed. Fifty-five percent were male, mean age 62.6±10.2 years, and mean estimated glomerular filtration rate (eGFR) 69.93±24.30 ml/min/1.73 m2). Incidents of CA-AKI, defined as an absolute increase of serum creatinine of at least 0.3 mg/dL within 48 hours or a relative increase of at least 50% within seven days after the procedure, were collected. The results showed that 78 patients (12.1%) had developed CA-AKI. Chen’s, Inohara’s, and Tziakas’ predictive risk models exhibited low discriminative ability with c-statistic of 0.571, 0.551, and 0.530, respectively. Due to low discriminative capability, these risk models may have low sensitivity to predict CA-AKI in Thai patients undergoing elective cardiac angiography or angioplasty.
Pharmaceutical Sciences AsiaPharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
0.90
自引率
0.00%
发文量
59
期刊介绍:
The Pharmaceutical Sciences Asia (PSA) journal is a double-blinded peer-reviewed journal in English published quarterly, by the Faculty of Pharmacy, Mahidol University, Thailand. The PSA journal is formerly known as Mahidol University Journal of Pharmaceutical Sciences and committed to the timely publication of innovative articles and reviews. This journal is available in both printed and electronic formats. The PSA journal aims at establishing a publishing house that is open to all. It aims to disseminate knowledge; provide a learned reference in the field; and establish channels of communication between academic and research expert, policy makers and executives in industry and investment institutions. The journal publishes research articles, review articles, and scientific commentaries on all aspects of the pharmaceutical sciences and multidisciplinary field in health professions and medicine. More specifically, the journal publishes research on all areas of pharmaceutical sciences and related disciplines: Clinical Pharmacy Drug Synthesis and Discovery Targeted-Drug Delivery Pharmaceutics Biopharmaceutical Sciences Phytopharmaceutical Sciences Pharmacology and Toxicology Pharmaceutical Chemistry Nutraceuticals and Functional Foods Natural Products Social, Economic, and Administrative Pharmacy Clinical Drug Evaluation and Drug Policy Making Antimicrobials, Resistance and Infection Control Pharmacokinetics and Pharmacodynamics.